ClinicalTrials.gg
RecruitingNCT06170697Updated Dec 20, 2023

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of Camrelizumab and Cisplatin in Head and Neck Squamous Cell Carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Mar 2023, registered Dec 2023).
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck — 8 open to participants now, 8 under way, 2 of them phase 3. camrelizumab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
7th of 13
46 · median 46
Started
2023
with 1 other
Phase 2
11 of 13
6 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 7th largest by planned enrollment, is one of 2 that started in 2023, is one of 11 in phase 2, and was the 10th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

8 of the 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing camrelizumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

Every year, about 6% of patients with malignant tumors are diagnosed as head and neck cancer. There are about 650000 new cases and 350000 deaths. A considerable number of patients have simple local recurrence in the short term after operation suggesting that the biological behavior of this kind of tumor is relatively more invasive and the overall prognosis is poor. This project intends to study the efficacy and safety of camrelizumab combined with concurrent chemoradiotherapy for short-term postoperative progression of head and neck squamous cell carcinoma.

Read the detailed description

Head and neck squamous cell carcinoma (HNSCC) refers to the general name of squamous cell carcinoma in head and neck organs except nasopharyngeal carcinoma. The main primary sites include oral cavity, oropharynx, hypopharynx, larynx and cervical esophagus. At present, the incidence rate of head and neck squamous cell carcinoma is the sixth most common malignant tumor in the world. Every year, about 6% of patients with malignant tumors are diagnosed as head and neck cancer. There are about 650000 new cases and 350000 deaths, of which squamous cell carcinoma accounts for more than 95%.

In daily clinical work, due to insufficient neck cleaning, slow postoperative incision recovery, long waiting time for treatment, untimely postoperative referral and other reasons, a considerable number of patients have simple local recurrence in the short term after operation (e.g. within 6 months) and before the start of planned adjuvant radiotherapy, so that the purpose of PORT has evolved from initial adjuvant treatment to palliative treatment, It also suggests that the biological behavior of this kind of tumor is relatively more invasive and the overall prognosis is poor. Based on the current clinical and research status, for HNSCC with local regional recurrence in a short time (\< 6 months) after operation, both local regional control and remote control must be considered in treatment。 Therefore, this project intends to study the efficacy and safety of camrelizumab combined with concurrent chemoradiotherapy for short-term postoperative progression of head and neck squamous cell carcinoma.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Sign written before implementing any test related processes;
  • 2.Male or female subjects aged from 18 to 70 years old;
  • 3.For head and neck squamous cell carcinoma after standard radical resection and neck lymph node dissection, the number of lymph node dissections is unlimited;
  • 4.No therapy was received before operation and no adjuvant therapy was received after operation;
  • 5.Local or regional recurrence has been confirmed by at least 2 radiographs and a pathological diagnosis is not required;
  • 6.The time of recurrence was less than 6 months from operation;
  • 7.Whole body imaging to rule out distant ;
  • 8. Performance Status (ECOG PS) of 0 to 1 at trial entry;
  • 9.Adequate haematological, hepatic and renal functions defined by the protocol;
  • 10.Estimated of more than 1year;
  • 11.No history of pD-1 or inhibitor treatment;
  • 12.No underlying diseases requiring therapy;
  • 13.PD-L1 status is not required, but PD-L1 IHC detection is recommended;
  • 14.Women of reproductive age must undergo a negative urinary pregnancy test within 7 days before starting treatment

Exclusion criteria

Exclusion Criteria:

  • 1.The primary site is squamous cell carcinoma of the nasopharynx or skin;
  • 2.Previous malignant disease within the last 5 years with the exception of basal or squamous cell carcinoma of the skin or carcinoma in situ (bladder, cervical, colorectal, breast);
  • 3.Currently participating in intervention clinical research treatment, or receiving other research drugs or using research instruments within 4 weeks before the first administration;
  • 4.Previously received , anti-PD-L1 or anti-PD-L2 drugs or drugs that stimulate or synergistically inhibit T cell receptors;
  • 5.Prior organ transplantation, including stem-cell transplantation(except corneal transplantation);
  • 6.Known history of allergy to the drug components of this regimen;
  • 7.There are multiple factors (e.g. severe renal insufficiency, bone marrow suppression) that influence the chemotherapeutic agent selected by the investigator;
  • 8.Before starting treatment, it has not fully recovered from the toxicity and / or complications caused by any intervention;
    1. Patients with congenital or acquired immune deficiency, such as (HIV) infection, Active tuberculosis, active (HBV DNA \<1000 copy/ml,200 IU/ml), (HCV antibody positive and HCV-RNA higher than the detection limit of the analytical method), or co infection of hepatitis B and hepatitis C;
  • 10.Accination with live or live/attenuated viruses within 4 weeks of the first dose of camrelizumab and while on trial is prohibited except for administration of inactivated vaccines;
  • 11.History of uncontrolled intercurrent illness including hypertension, active infection, diabetes , hereditary bleeding , coagulopathy with a risk of bleedingor, cardiac diseases or symptoms;
  • 12.Patients with past and current interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-associated pneumonia, and severe impaired lung function may interfere with the detection and management of suspected drug-associated pulmonary toxicity;
  • 13.Any active disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy)); The subjects with childhood asthma who had been completely relieved and did not need any intervention or vitiligo in adulthood could be included, but the subjects who needed bronchodilator for medical intervention could not be included;
  • 14.Used drugs within 14 days before the first dose of study drug, excluding nasal and inhaled or physiological doses of systemic corticosteroids;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Camrelizumab+(Cisplatin or Carboplatin or Lobaplatin or Nedaplatin)+radiotherapy

    patients with short-term postoperative progression receive camrelizumab and platin-based chemotherapy concurrent with radiotherapy.

    Drug: Camrelizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: Lobaplatin · Drug: Nedaplatin · Radiation: Radiotherapy

Interventions

  • 200mg, iv, d1, q3w

    Also known as: immunotherapy

  • 80-100mg/m2, iv, q3w, 2-3 cycles in total

    Also known as: chemotherapy

  • AUC 2, iv, q1w, 5-7 cycles in total

    Also known as: chemotherapy

  • 30mg/m2, iv, q3w, 2-3 cycles in total

    Also known as: chemotherapy

  • 25-30 mg/m2, iv, q1w, 5-7 cycles in total

    Also known as: chemotherapy

  • RadiationRadiotherapy

    PGTVp/PGTVnd 66-70Gy/2-2.2Gy/30-35F;PTV1 60Gy/1.8-2.0Gy/30-33F;PTV2 50Gy/1.8-20Gy/25-28F;Start 1-2 weeks after the start of immunotherapy, 1 time before the start of simultaneous chemotherapy, up to 3 times during the concurrent chemoradiotherapy

    Also known as: radiation therapy

06

What researchers measure

Primary outcomes

  1. 1 year Progression-free survival (1y-PFS)

    Proportion of patients with disease-free survival at 3 years after randomization

    Time frame: up to 1 years

Secondary outcomes

  1. Objective Response Rate(ORR)

    Assess ORR, defined as Investigator-assessed CR + PR, per RECIST 1.1.

    Time frame: From the start of randomization to a minimum of 24 months

  2. Disease Control Rate (DCR)

    Percentage of patients with CR/PR/SD in the number of patients that whose tumour can be evaluated

    Time frame: From the start of randomization to a minimum of 24 months

  3. Duration of Response (DoR)

    DoR is defined as the time from the measurement of the first compliance with Cr or pr (whichever occurs first) to the first true recording of disease recurrence or progression.

    Time frame: From the start of randomization to a minimum of 48 months

  4. Overall survival (OS)

    OS is defined as the time (in months) from randomization to the date of death, regardless of the actual cause of the subject's death.

    Time frame: From the start of randomization to a minimum of 48 months

  5. Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

    TEAEs will be defined as the adverse events (AEs) that occur between first dose of study drug administration and 28 days after the last dose of study drug administration that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: From the the first dose of study drug administration up to 28 days after the last dose of study drug administration, assessed up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing 100020, China
    Recruiting
    • Jingbo Wang, PhD · Contactgldanna@163.com · +8618500369703
    • Jingbo Wang · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — IPD will be avaliable upon request to PI

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jul 2024, 16 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 16 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 14, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Jul 2024
CompletionEst.
Jul 2025
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06170697
Responsible party
Sponsor
First posted
Dec 14, 2023
Start date
Mar 1, 2023
Primary completion
Jul 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Dec 20, 2023

Study contacts

Jingbo Wang
Contact
wangjingbo201001@163.com
+8618500369703
Gulidanna Shayan
Contact
gldanna@163.com
18500369703
Jingbo Wang
principal investigator · Chinese academy of medical science, cancer hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion